Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND TP63, EEC3, 8626, ENSG00000073282, p73H, p63, Q9H3D4, TP73L, p51, OFC8, KET, RHS, B p51B , B p51A , SHFM4, LMS, p73L AND Treatment
41 results:

  • 1. Single protein encapsulated SN38 for tumor-targeting treatment.
    Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
    J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. High grade leiomyosarcoma of the transverse colon with positive lymph node metastasis: to treat or not to treat with adjuvant radiation therapy?
    Jenkins P; Joiner M; Kumar A; Miller SR
    BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37336627
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Construction and validation of a novel Ferroptosis-related gene signature predictive model in rectal cancer.
    Shi WK; Liu YX; Qiu XY; Zhou JY; Zhou JL; Lin GL
    BMC Genomics; 2022 Nov; 23(1):764. PubMed ID: 36414988
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2022 Dec; 30(12):10203-10211. PubMed ID: 36217043
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The double challenge (preoperative diagnosis and surgical approach) of primary leiomyosarcoma of the sigmoid colon.
    Lorenzo Pagliai ; Annicchiarico A; Morini A; Montali F; Virgilio E; Costi R
    Acta Biomed; 2022 Apr; 93(S1):e2022124. PubMed ID: 35421072
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A systematic and comprehensive analysis of colorectal squamous cell carcinoma: Implication for diagnosis and treatment.
    Yang Y; Yu J; Hu J; Zhou C; Niu J; Ma H; Han J; Fan S; Liu Y; Zhao Y; Zhao L; Wang G
    Cancer Med; 2022 Jun; 11(12):2492-2502. PubMed ID: 35194959
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Shikonin induces cell autophagy via modulating the microRNA -545-3p/guanine nucleotide binding protein beta polypeptide 1 axis, thereby disrupting cellular carcinogenesis in colon cancer.
    Hu Z; Zhou X; Zeng D; Lai J
    Bioengineered; 2022 Mar; 13(3):5928-5941. PubMed ID: 35192430
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Clinicopathological analysis of lung metastatic tumor].
    Lou N; Niu YR; Yang F; Lu ZH
    Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1039-1044. PubMed ID: 34496496
    [No Abstract]    [Full Text] [Related]  

  • 9. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
    Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
    Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Inhibitor of apoptosis-stimulating p53 protein protects against inflammatory bowel disease in mice models by inhibiting the nuclear factor kappa B signaling.
    Qian K; Yuan L; Wang S; Kuang Y; Jin Q; Long D; Jiang Y; Zhao H; Liu K; Yao H
    Clin Exp Immunol; 2021 Aug; 205(2):246-256. PubMed ID: 33942299
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Surgical resection improves overall survival of patients with small bowel leiomyosarcoma.
    Welten VM; Fields AC; Lu PW; Yoo J; Goldberg JE; Irani J; Bleday R; Melnitchouk N
    Int J Colorectal Dis; 2020 Dec; 35(12):2283-2291. PubMed ID: 32812089
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Disappearing liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Paredes AZ; Moris D; Gavriatopoulou M; Cloyd JM; Pawlik TM
    Surg Oncol; 2019 Jun; 29():7-13. PubMed ID: 31196496
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Primary leiomyosarcoma of the colon: a case report and review of the literature.
    Devriendt S; Leman G; Vanrykel F
    Acta Chir Belg; 2020 Oct; 120(5):353-356. PubMed ID: 30879400
    [No Abstract]    [Full Text] [Related]  

  • 14. Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.
    Vidarsdottir H; Tran L; Nodin B; Jirström K; Planck M; Jönsson P; Mattsson JSM; Botling J; Micke P; Brunnström H
    Hum Pathol; 2019 Feb; 84():221-230. PubMed ID: 30389437
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
    Peng Y; Chen Y; Zhang X; Yang Y; Cao D; Bi F; Li Z; Gou H
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1339-1346. PubMed ID: 29774414
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Type of adjuvant chemotherapy and treatment frequency in survival outcome of patients with colorectal liver metastases who underwent liver metastasectomy: an 8-year cohort study in Taiwan.
    Huang YF; Chiang HY; Chang SN; Chiang FF
    Int J Colorectal Dis; 2018 Jul; 33(7):985-989. PubMed ID: 29619561
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Primary leiomyosarcoma in the colon: A case report.
    Yang J
    Medicine (Baltimore); 2018 Feb; 97(7):e9923. PubMed ID: 29443772
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
    Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Prognostic value of the lymphocyte monocyte ratio in patients with colorectal cancer: A meta-analysis.
    Song W; Wang K; Zhang RJ; Zou SB
    Medicine (Baltimore); 2016 Dec; 95(49):e5540. PubMed ID: 27930549
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Pathology of Anal cancer.
    Hoff PM; Coudry R; Moniz CM
    Surg Oncol Clin N Am; 2017 Jan; 26(1):57-71. PubMed ID: 27889037
    [TBL] [Abstract] [Full Text] [Related]  


    of 3.